Components:
Method of action:
Treatment option:
Medically reviewed by Oliinyk Elizabeth Ivanovna, PharmD. Last updated on 05.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
1. Folate deficient megaloblastic anaemia
2. Folate deficient megaloblastic anaemia in infants
3. Treatment of folate deficiency in malabsorption syndromes (parenteral administration of Ac.Folicum Uman vitamini may need to be considered if oral treatment is not effective)
3.1 Tropical sprue. Tropical sprue responds to folate supplements in the early stages of the disease but cobalamin status must also be checked, particularly later.
3.2 Coeliac disease. The necessity of supplementation with folate ceases once a gluten free diet is introduced.
3.3 Non-tropical sprue. In congenital folate malabsorption, oral treatment may not be effective and parental folate may therefore be required.
4. Megaloblastic anaemia in pregnancy
5. Megaloblastic anaemia associated with alcoholism
6. Megaloblastic anaemia associated with anti-convulsant therapy
7. Ac.Folicum Uman vitamini deficiency/megaloblastic anaemia associated with haemolytic anaemia e.g. Sickle Cell Anaemia
For oral administration only.
Children (persons aged 12 years and younger):
May be given 5 mg to 15 mg daily, in divided doses, according to the severity of the deficiency state.
Adults:
Initial dose of 10 mg to 20 mg daily, in divided doses, for 14 days or until a haemopotoietic response has been obtained.
Maintenance dose is 2.5 mg to 10 mg daily.
Prophylactic dose in pregnancy 0.5 mg (1ml) daily.
Elderly:
As for adults.
Known hypersensitivity to Ac.Folicum Uman vitamini.
Known hypersensitivity to hydroxybenzoate esters.
Patients with malignant disease, unless megaloblastic anaemia due to Ac.Folicum Uman vitamini deficiency.
Ac.Folicum Uman vitamini should not be administered for treatment of pernicious anaemia or undiagnosed megaloblastic anaemia without sufficient amounts of cyanocobalamin (vitamin B12) as Ac.Folicum Uman vitamini alone will not prevent and may precipitate development of subacute combined degeneration of the spinal cord. Therefore a full clinical diagnosis should be made before initiating treatment.
Folate should not be routinely used in patients receiving coronary stents.
Caution should be exercised when administering Ac.Folicum Uman vitamini to patients who may have folate dependent tumours.
Ac.Folicum Uman vitamini is removed by haemodialysis.
Contains methyl- ethyl- and propyl- p-hydroxybenzoates; may cause allergic reactions (possibly delayed).
Contains 0.75 mmol (or 17.4mg) sodium per 20 ml dose, and is therefore essentially 'sodium-free'.
Contains phenylalanine. May be harmful for people with phenylketonuria.
There are no known effects of this preparation on the ability to drive or use machines.
Ac.Folicum Uman vitamini is generally well tolerated, although the following side effects have been reported:
Blood and lymphatic system disorders:
Ac.Folicum Uman vitamini may worsen the symptoms of co-existing vitamin B12 deficiency and should never be used to treat anaemia without a full investigation of the cause.
Immune system disorders:
Allergic reactions to Ac.Folicum Uman vitamini have been reported.
Gastrointestinal disorder:
Abdominal distension, flatulence, anorexia and nausea.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
No cases of acute overdosage appear to have been reported, but even extremely high doses are unlikely to cause harm to patients. No special procedures or antidote are likely to be needed.
ATC Code: B03B B
After conversion into co-enzyme forms it is concerned in single carbon unit transfers in the synthesis of purines, pyrimidines and methionine.
About 70 - 80 % of a 2 mg oral solution of Ac.Folicum Uman vitamini is absorbed. Larger doses are probably equally well absorbed. It is distributed into plasma and extracellular fluid. In plasma, folate is bound weakly to albumin (70 %). There is a further high affinity binder for folate but this has a very low capacity and is barely detectable in normal sera. About 70 % of small doses of folate (about 1 mg) are retained and the rest excreted into the urine. With larger doses most is excreted into the urine. With a 5 mg dose of folate, urinary excretion will be complete in about five hours. There is an enterohepatic circulation of folate. The retained folate is taken into cells and reduced by dihydrofolate to tetrahydrofolate. Ac.Folicum Uman vitamini is a relatively poor substrate for folate reduction, the normal substrate being dihydrofolate.
Ac.Folicum Uman vitamini itself does not occur in natural materials, it is entirely a pharmacological form of the compound. Once reduced, folate has additional glutamic acid residues added, a folate pentaglutamate being the dominant intracellular analogue. These polyglutamates are the active co-enzymes.
Ac.Folicum Uman vitamini is a drug on which extensive clinical experience has been obtained. Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.
None stated.
Not applicable.
Interpretation of Folate Results in Hemolytic Plasma Samples: A Practical Approach
Perceptions of Lady Health Workers and their trainers about their curriculum for implementing the interventions identified for Essential Package of Health Services for Pakistan
Estrogenicity of chemical mixtures revealed by a panel of bioassays
Assessing multiple sclerosis-related quality of life among Iranian patients using the MSQOL-54 tool: a cross-sectional study
Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer’s Disease Dementia
Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer
Small RNA sequencing evaluation of renal microRNA biomarkers in dogs with X-linked hereditary nephropathy
Evaluation of the safety and nutritional equivalency of maize grain with genetically modified event DP-Ø23211-2
Maternal mortality reduction: a need to focus actions on the prevention of hypertensive disorders of pregnancy
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma
Indirect effects of COVID-19 on maternal, neonatal, child, sexual and reproductive health services in Kampala, Uganda
Antioxidant supplements in age-related macular degeneration: are they actually beneficial?
The Relationship of Drug Therapy to Aplastic Anemia in Pakistan: A Hospital-Based Case Control Study
The weak correlation between serum vitamin levels and chronic kidney disease in hospitalized patients: a cross-sectional study
Pertinence of nutriments for a stalwart body
Emerging Trends in Nanomaterials for Antibacterial Applications
Acacia hydaspica R. Parker ethyl-acetate extract abrogates cisplatin-induced nephrotoxicity by targeting ROS and inflammatory cytokines
Educational Case: Understanding Kwashiorkor and Marasmus: Disease Mechanisms and Pathologic Consequences
Safety of frozen and dried formulations from whole yellow mealworm (Tenebrio molitor larva) as a novel food pursuant to Regulation (EU) 2015/2283
The Antioxidant Effect of Medicago sativa L. (Alfalfa) Ethanolic Extract against Mercury Chloride (HgCl2) Toxicity in Rat Liver and Kidney: An In Vitro and In Vivo Study
However, we will provide data for each active ingredient